682 related articles for article (PubMed ID: 27533882)
21. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
22. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
Offidani M; Corvatta L
Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
[TBL] [Abstract][Full Text] [Related]
23. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Passey C; Mora J; Dodge R; Gibiansky L; Sheng J; Roy A; Bello A; Gupta M
AAPS J; 2017 Mar; 19(2):557-567. PubMed ID: 28070715
[TBL] [Abstract][Full Text] [Related]
24. Elotuzumab for the treatment of multiple myeloma.
Moreau P; Touzeau C
Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
[TBL] [Abstract][Full Text] [Related]
25. Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.
Eleutherakis-Papaiakovou E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Kastritis E; Terpos E; Dimopoulos MA
Expert Rev Anticancer Ther; 2019 Nov; 19(11):921-928. PubMed ID: 31679403
[No Abstract] [Full Text] [Related]
26. Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Laubach JP; Paba Prada CE; Richardson PG; Longo DL
Clin Pharmacol Ther; 2017 Jan; 101(1):81-88. PubMed ID: 27806428
[TBL] [Abstract][Full Text] [Related]
27. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
28. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Richardson PG; Beksaç M; Špička I; Mikhael J
Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
[TBL] [Abstract][Full Text] [Related]
29. Elotuzumab for the treatment of multiple myeloma.
Wang Y; Sanchez L; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
[TBL] [Abstract][Full Text] [Related]
30. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
Kikuchi J; Hori M; Iha H; Toyama-Sorimachi N; Hagiwara S; Kuroda Y; Koyama D; Izumi T; Yasui H; Suzuki A; Furukawa Y
Leukemia; 2020 Jan; 34(1):180-195. PubMed ID: 31358854
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Berdeja J; Jagannath S; Zonder J; Badros A; Kaufman JL; Manges R; Gupta M; Tendolkar A; Lynch M; Bleickardt E; Paliwal P; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):129-38. PubMed ID: 26795075
[TBL] [Abstract][Full Text] [Related]
32. Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.
Iqbal SM; Stecklein K; Sarow J; Krabak M; Hillengass J; McCarthy P
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e33-e36. PubMed ID: 30337238
[No Abstract] [Full Text] [Related]
33. A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Berenson J; Manges R; Badarinath S; Cartmell A; McIntyre K; Lyons R; Harb W; Mohamed H; Nourbakhsh A; Rifkin R
Am J Hematol; 2017 May; 92(5):460-466. PubMed ID: 28213943
[TBL] [Abstract][Full Text] [Related]
34. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
[TBL] [Abstract][Full Text] [Related]
35. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
Einsele H; Schreder M
Ther Adv Hematol; 2016 Oct; 7(5):288-301. PubMed ID: 27695618
[TBL] [Abstract][Full Text] [Related]
36. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Moreau P; de Wit E
Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
[TBL] [Abstract][Full Text] [Related]
37. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Gormley NJ; Ko CW; Deisseroth A; Nie L; Kaminskas E; Kormanik N; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2017 Nov; 23(22):6759-6763. PubMed ID: 28249893
[TBL] [Abstract][Full Text] [Related]
38. The Clinical Pharmacology of Elotuzumab.
Passey C; Sheng J; Mora J; Tendolkar A; Robbins M; Dodge R; Roy A; Bello A; Gupta M
Clin Pharmacokinet; 2018 Mar; 57(3):297-313. PubMed ID: 28779463
[TBL] [Abstract][Full Text] [Related]
39. Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.
Danhof S; Strifler S; Hose D; Kortüm M; Bittrich M; Hefner J; Einsele H; Knop S; Schreder M
J Cancer Res Clin Oncol; 2019 Mar; 145(3):561-571. PubMed ID: 30519736
[TBL] [Abstract][Full Text] [Related]
40. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
